In a patient with DLBCL who previously developed G-CSF-associated vasculitis, re-administration of filgrastim and pegfilgrastim without recurrence was deemed feasible after achieving durable control of inflammation with corticosteroids and a 14-month interval. The gene discussed is CSF3; the disease is diffuse large B-cell lymphoma.